Latest & greatest articles for corticosteroids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on corticosteroids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on corticosteroids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for corticosteroids

501. Calcium and vitamin D for corticosteroid-induced osteoporosis. Full Text available with Trip Pro

Calcium and vitamin D for corticosteroid-induced osteoporosis. To assess the effects of calcium and vitamin D compared to calcium alone or placebo in the prevention of bone loss in patients taking systemic corticosteroids.We searched the Cochrane Musculoskeletal trials register, Cochrane Controlled Trials Register, EMBASE and Medline up to 1996. We also conducted a hand search of abstracts from various scientific meetings and reference lists of selected trials.All randomized trials comparing (...) ), and radial bone mineral density (WMD 2.5 (95% CI 0.6, 4.4). The other outcome measures (femoral neck bone mass, fracture incidence, biochemical markers of bone resorption) were not significantly different.This meta-analysis demonstrated a clinically and statistically significant prevention of bone loss at the lumbar spine and forearm with vitamin D and calcium in corticosteroid treated patients. Because of low toxicity and cost all patients being started on corticosteroids should receive prophylactic

2000 Cochrane

502. What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD?

of corticosteroids on time to discharge, adverse events or quality of life. - We are unable to reach conclusions regarding the dosing effect for intravenous and oral corticosteroids individually. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Adrenal Cortex Hormones; Asthma /drug therapy; Pulmonary Disease, Chronic Obstructive /drug therapy Language Published English Country of organisation Australia Address for correspondence Monash Institute of Health Services Research, Block E, Monash (...) What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD? What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD? What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD? Hender K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality

2000 Health Technology Assessment (HTA) Database.

503. Inhaled corticosteroids for asthma

therapeutic interchange. Each monograph includes comprehensive information from the primary literature and provides recommendations for appropriate use. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Administration, Inhalation; Adrenal Cortex Hormones; Asthma /drug therapy Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954-1700; Fax: 630-954 (...) Inhaled corticosteroids for asthma Inhaled corticosteroids for asthma Inhaled corticosteroids for asthma Weber J Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Weber J. Inhaled corticosteroids for asthma. University HealthSystem Consortium (UHC). Drug Monograph. 2000 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise

2000 Health Technology Assessment (HTA) Database.

504. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children

Heuschkel R B, Menache C C, Megerian J T, Baird A E. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. Journal of Pediatric Gastroenterology and Nutrition 2000; 31(1): 8-15 PubMedID Original Paper URL Other publications of related interest Griffiths AM. Enteral nutrition: the neglected primary therapy of active Crohn's Disease. J Pediatr Gastroenterol Nutr 2000;31:3-5. Indexing Status Subject indexing assigned by NLM MeSH Acute Disease; Adolescent; Adrenal (...) Cortex Hormones /adverse effects /therapeutic use; Child; Child, Preschool; Clinical Trials as Topic; Crohn Disease /therapy; Enteral Nutrition; Female; Humans; Male; Remission Induction; Risk; Treatment Outcome AccessionNumber 12000001381 Date bibliographic record published 31/12/2001 Date abstract record published 31/12/2001 Record Status This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review

2000 DARE.

505. Eficacia de los glucocorticoides en las reagudizaciones de la enfermedad pulmonar obstructiva cronica: metaanalisis de los estudios publicados [The efficacy of corticosteroids in exacerbations of chronic obstructive pulmonary disease: meta-analysis of pub

Clinica 2000; 114(18): 681-684 PubMedID Other publications of related interest Casan P, Belda J. Glucocorticoides en el tratamiento de la enfermedad pulmonar obstructiva cronica (Glucocorticoids in the treatment of chronic obstructive pulmonary disease). Med Clin 2000;114:694-5. Indexing Status Subject indexing assigned by NLM MeSH Adrenal Cortex Hormones /therapeutic use; Clinical Trials as Topic; Drug Administration Routes; Humans; Lung Diseases, Obstructive /drug therapy; MEDLINE; Time Factors (...) Eficacia de los glucocorticoides en las reagudizaciones de la enfermedad pulmonar obstructiva cronica: metaanalisis de los estudios publicados [The efficacy of corticosteroids in exacerbations of chronic obstructive pulmonary disease: meta-analysis of pub Eficacia de los glucocorticoides en las reagudizaciones de la enfermedad pulmonar obstructiva cronica: metaanalisis de los estudios publicados [The efficacy of corticosteroids in exacerbations of chronic obstructive pulmonary disease: meta

2000 DARE.

506. Pharmacoeconomic impact of inhaled corticosteroids

Pharmacoeconomic impact of inhaled corticosteroids Pharmacoeconomic impact of inhaled corticosteroids Pharmacoeconomic impact of inhaled corticosteroids Stempel D A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use (...) of three inhaled corticosteroids (ICSs) for the treatment of persistent asthma. The ICSs were fluticasone, triamcinolone and zafirlukast. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients suffering from persistent asthma, as defined by the International Classification of Diseases, 9th Revision (ICD-9) code (493.XX). Setting The setting of the study appears to have been the community. The economic study was carried

2000 NHS Economic Evaluation Database.

507. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology

the prognosis for patients with MS. Bibliographic details Kaufman D I, Trobe J D, Eggenberger E R, Whitaker J N. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54(11): 2039-2044 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Academies and Institutes; Adrenal Cortex Hormones; Anti-Inflammatory Agents /therapeutic use; Humans (...) Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report

2000 DARE.

508. Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function

2000; 36(2): 101-107 PubMedID Other publications of related interest 1. Sinclair JC, Bracken MB, Soll RF, Horbar JD, editors. Cochrane Neonatal Group. Search strategy for specialized register. In: The Cochrane Library, Issue 1, 1999. Oxford: Update Software. Indexing Status Subject indexing assigned by NLM MeSH Adrenal Cortex Hormones /adverse effects /therapeutic use; Cerebral Palsy /chemically induced /mortality; Disease-Free Survival; Female; Humans; Infant, Newborn; Infant, Premature; Motor (...) Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function Doyle L W, Davis P G Authors' objectives To review the evidence on the effects of postnatal corticosteroids in preterm infants on long-term mortality and motor dysfunction

2000 DARE.

509. Systemic corticosteroids in infant bronchiolitis: a meta-analysis

Register (as of January 1999), and EMBASE from January 1990 to January 1999. The search terms included 'bronchiolitis', 'respiratory syncytial viruses', 'adrenal cortex hormones', 'corticosteroid', 'glucocorticoid', 'antiinflammatory agents' and 'steroidal'. The bibliographies of review articles and all selected articles were examined. No language restrictions were reported. Study selection Study designs of evaluations included in the review Randomised placebo-controlled studies. The studies had (...) Systemic corticosteroids in infant bronchiolitis: a meta-analysis Systemic corticosteroids in infant bronchiolitis: a meta-analysis Systemic corticosteroids in infant bronchiolitis: a meta-analysis Garrison M M, Christakis D A, Harvey E, Cummings P, Davis R L Authors' objectives To determine whether corticosteroids are efficacious in treating bronchiolitis in hospitalised infants. Searching The following sources were searched: MEDLINE from 1966 to January 1999, the Cochrane Controlled Trials

2000 DARE.

510. Corticosteroid treatment for idiopathic facial nerve paralysis: a meta-analysis

Corticosteroid treatment for idiopathic facial nerve paralysis: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2000 DARE.

511. Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis

Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis Solomon D H, Kuntz K M Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This paper compared three strategies, namely waiting, screening and treating, for the prevention of corticosteroid-induced osteoporosis in postmenopausal women with rheumatoid arthritis (RA

2000 NHS Economic Evaluation Database.

512. The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis

1994;37 Suppl 9:S429. Indexing Status Subject indexing assigned by NLM MeSH Administration, Oral; Adrenal Cortex Hormones /administration & Chicago; Child, Preschool; Cost Savings; Cost of Illness; Cost-Benefit Analysis; Dermatomyositis /drug therapy /economics; Direct Service Costs /statistics & Drug Costs /statistics & Female; Health Resources /economics /utilization; Hospital Costs /statistics & Hospitals, Pediatric; Humans; Infusions, Intravenous /economics; Length of Stay /economics; Male (...) The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis Klein-Gitelman M S, Waters T, Pachman L M Record Status This is a critical abstract of an economic evaluation that meets

2000 NHS Economic Evaluation Database.

513. Systemic Corticosteroids in Infant Bronchiolitis: A Meta-analysis

Systemic Corticosteroids in Infant Bronchiolitis: A Meta-analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2000 PedsCCM Evidence-Based Journal Club

514. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. (Abstract)

Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. Relapses of acute asthma following emergency department (ED) discharge can be reduced with systemic corticosteroid treatment. However, whether inhaled corticosteroids (ICSs) provide additional benefit is not known. Objective To determine whether the addition of ICSs to oral corticosteroid treatment would reduce relapses in patients (...) with acute asthma discharged from the ED.Placebo-controlled, double-blind, randomized clinical trial conducted in a community teaching hospital ED in Canada between November 1995 and September 1997, with a 21-day follow-up.A total of 1006 consecutive patients aged 16 to 60 years presented to the ED with acute asthma; after excluding those using oral and/or inhaled corticosteroids as well as those meeting other exclusion criteria, 188 were included in the study.Patients were discharged with a nontapering

1999 JAMA Controlled trial quality: predicted high

515. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. (Abstract)

Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. The role of oral corticosteroids in treating patients with exacerbations of chronic obstructive pulmonary disease (COPD) remains contentious. We assessed in a prospective, randomised, double-blind, placebo-controlled trial the effects of oral corticosteroid therapy in patients with exacerbations of COPD requiring hospital admission.We (...) stay was analysed by intention to treat and forced expiratory volume in 1 s (FEV1) according to protocol.FEV1 after bronchodilation increased more rapidly and to a greater extent in the corticosteroid-treated group: percentage predicted FEV1 after bronchodilation rose from 25.7% (95% CI 21.0-30.4) to 32.2% (27.3-27.1) in the placebo group (p<0.0001) compared with 28.2% (23.5-32.9) to 41.5% (35.8-47.2) in the corticosteroid-treated group (p<0.0001). Up to day 5 of hospital stay, FEV1 after

1999 Lancet Controlled trial quality: predicted high

516. Methods to encourage the use of antenatal corticosteroid therapy for fetal maturation: a randomized controlled trial. (Abstract)

Methods to encourage the use of antenatal corticosteroid therapy for fetal maturation: a randomized controlled trial. Antenatal corticosteroids for fetal maturation have been underused, despite evidence for their benefits in cases of preterm birth.To evaluate dissemination strategies aimed at increasing appropriate use of this therapy.Twenty-seven tertiary care institutions were randomly assigned to either usual dissemination of practice recommendations (n = 14) or usual dissemination plus (...) and a nurse coordinator at each facility, consisting of grand rounds, a chart reminder system, group discussion of case scenarios, monitoring, and feedback.Use or nonuse of antenatal corticosteroids was abstracted from medical records of eligible women delivering at the participating hospitals in the 12 months immediately prior to release of the NIH recommendations (average number of records abstracted, 130) and in the 12 months following their release (average number of records abstracted, 122).Active

1999 JAMA Controlled trial quality: uncertain

517. Corticosteroids in IgA nephropathy: a randomised controlled trial. (Abstract)

Corticosteroids in IgA nephropathy: a randomised controlled trial. IgA nephropathy is progressive in most cases and has no established therapy. In this randomised trial, we assessed the efficacy and safety of a 6-month course of steroids in this disorder.Between July, 1987, and September, 1995, we enrolled 86 consecutive patients from seven renal units in Italy. Eligible patients had biopsy-proven IgA nephropathy, urine protein excretion of 1.0-3.5 g daily, and plasma creatinine concentrations

1999 Lancet Controlled trial quality: predicted high

518. Pragmatic randomised controlled trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis of elbow in primary care. Full Text available with Trip Pro

Pragmatic randomised controlled trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis of elbow in primary care. To compare the clinical effectiveness of local corticosteroid injection, standard non-steroidal anti-inflammatory drugs, and simple analgesics for the early treatment of lateral epicondylitis in primary care.Multicentre pragmatic randomised controlled trial.23 general practices in North Staffordshire and South Cheshire.164 patients aged 18-70 (...) to injection, 53 to naproxen, and 58 to placebo. Prognostic variables were similar between groups at baseline. At 4 weeks, 48 patients (92%) in the injection group were completely better or improved compared with 30 (57%) in the naproxen group (P<0.001) and 28 (50%) in the placebo group (P<0.001). At 12 months, 43 patients (84%) in the injection group had pain scores 0.05).Early local corticosteroid injection

1999 BMJ Controlled trial quality: predicted high

519. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. Full Text available with Trip Pro

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. To determine the ability of montelukast, a leukotriene receptor antagonist, to allow tapering of inhaled corticosteroids in clinically stable asthmatic patients.Double blind, randomised, placebo controlled, parallel group study. After a single blind placebo run in period, during which (at most) two inhaled corticosteroids dose decreases (...) occurred, qualifying, clinically stable patients were allocated randomly to receive montelukast (10 mg tablet) or matching placebo once daily at bedtime for up to 12 weeks.23 academic asthma centres in United States, Canada, and Europe.226 clinically stable patients with chronic asthma receiving high doses of inhaled corticosteroids (113 randomised to montelukast and 113 to placebo).Every 2 weeks, the inhaled corticosteroids dose was tapered, maintained, or increased (rescue) based on a standardised

1999 BMJ Controlled trial quality: predicted high

520. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis

studies for the skin effects endpoints. The number of studies for the ocular end point is not clear in the discussion. Marked adrenal suppression occurs with high doses of inhaled corticosteroid above 1.5 mg/d (0.75 mg/d for fluticosone propionate) although there is a considerable degree of interindividual susceptability. Meta-analysis showed significantly greater potency for dose-related adrenal suppression with fluticasone compared with beclomethasone dipropionate, budesonide, or triamcinolone (...) significant effects on final audit height. Long-term, high-dose inhaled corticosteroids exposure increases the risk for posterior subcapsular cataracts, and, to a much lesser degree, the risk for ocular hypertension and glaucoma. Skin bruising is most likely to occur with high-dose exposure, which correlates with the degree of adrenal suppression. Authors' conclusions The authors state that all inhaled corticosteroids exhibit dose- related systemic adverse effects, although these are less than

1999 DARE.